» Articles » PMID: 24004523

Consensus-based Recommendations for Investigating Clinical Heterogeneity in Systematic Reviews

Overview
Publisher Biomed Central
Date 2013 Sep 6
PMID 24004523
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Critics of systematic reviews have argued that these studies often fail to inform clinical decision making because their results are far too general, that the data are sparse, such that findings cannot be applied to individual patients or for other decision making. While there is some consensus on methods for investigating statistical and methodological heterogeneity, little attention has been paid to clinical aspects of heterogeneity. Clinical heterogeneity, true effect heterogeneity, can be defined as variability among studies in the participants, the types or timing of outcome measurements, and the intervention characteristics. The objective of this project was to develop recommendations for investigating clinical heterogeneity in systematic reviews.

Methods: We used a modified Delphi technique with three phases: (1) pre-meeting item generation; (2) face-to-face consensus meeting in the form of a modified Delphi process; and (3) post-meeting feedback. We identified and invited potential participants with expertise in systematic review methodology, systematic review reporting, or statistical aspects of meta-analyses, or those who published papers on clinical heterogeneity.

Results: Between April and June of 2011, we conducted phone calls with participants. In June 2011 we held the face-to-face focus group meeting in Ann Arbor, Michigan. First, we agreed upon a definition of clinical heterogeneity: Variations in the treatment effect that are due to differences in clinically related characteristics. Next, we discussed and generated recommendations in the following 12 categories related to investigating clinical heterogeneity: the systematic review team, planning investigations, rationale for choice of variables, types of clinical variables, the role of statistical heterogeneity, the use of plotting and visual aids, dealing with outlier studies, the number of investigations or variables, the role of the best evidence synthesis, types of statistical methods, the interpretation of findings, and reporting.

Conclusions: Clinical heterogeneity is common in systematic reviews. Our recommendations can help guide systematic reviewers in conducting valid and reliable investigations of clinical heterogeneity. Findings of these investigations may allow for increased applicability of findings of systematic reviews to the management of individual patients.

Citing Articles

High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed or refractory testicular cancer: a systematic review and meta-analysis.

Briones J, Diaz P, Nicholson B Front Oncol. 2024; 14:1437574.

PMID: 39411122 PMC: 11473300. DOI: 10.3389/fonc.2024.1437574.


The Cumulative Incidence of Post-Traumatic Epilepsy After Mild Traumatic Brain Injury: A Systematic Review and Individual Participant Data Meta-Analysis Protocol.

Goldenberg J, Batson R, Pugh M, Zwickey H, Beardsley J, Zeegers M Neurotrauma Rep. 2024; 5(1):522-528.

PMID: 39036430 PMC: 11257128. DOI: 10.1089/neur.2023.0117.


Assessment of the information provided by ChatGPT regarding exercise for patients with type 2 diabetes: a pilot study.

Chung S, Chang M BMJ Health Care Inform. 2024; 31(1).

PMID: 38964828 PMC: 11227747. DOI: 10.1136/bmjhci-2023-101006.


Efficiency of Protective Interventions on Irinotecan-Induced Diarrhea: A Systematic Review and Meta-Analysis.

He Y, Wu L, Qi X, Wang X, He B, Zhang W Integr Cancer Ther. 2024; 23:15347354241242110.

PMID: 38567795 PMC: 10993684. DOI: 10.1177/15347354241242110.


Safety and efficacy of fixed versus variable-dose prothrombin complex concentrate for emergent reversal of vitamin K antagonists: A systematic review and meta-analysis.

Condeni M, Weant K, Neyens R, Eriksson E, Miano T Am J Emerg Med. 2023; 77:91-105.

PMID: 38118388 PMC: 11441425. DOI: 10.1016/j.ajem.2023.11.066.


References
1.
Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

2.
Huizenga H, Visser I, Dolan C . Testing overall and moderator effects in random effects meta-regression. Br J Math Stat Psychol. 2011; 64(Pt 1):1-19. DOI: 10.1348/000711010X522687. View

3.
Furlan A, Pennick V, Bombardier C, van Tulder M . 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine (Phila Pa 1976). 2009; 34(18):1929-41. DOI: 10.1097/BRS.0b013e3181b1c99f. View

4.
Hall J, Rosenthal R . Interpreting and evaluating meta-analysis. Eval Health Prof. 1995; 18(4):393-407. DOI: 10.1177/016327879501800404. View

5.
Chalmers I, Glasziou P . Avoidable waste in the production and reporting of research evidence. Lancet. 2009; 374(9683):86-9. DOI: 10.1016/S0140-6736(09)60329-9. View